INTRODUCTION: Fibrinogen is a plasma glycoprotein that participates in the hemostasis system. Its malfunction has been reported as a consequence of diabetic complications. In this study, the inhibitory effect of L-Lysine (Lys) on the nonenzymatic glycation of fibrinogen was investigated in both in vitro and in vivo conditions. MATERIALS AND METHODS: Fibrinogen was incubated with glucose in the presence or absence of Lys. Then, its structure was studied by fluorescence spectroscopy, circular dichroism, and electrophoresis. The Clauss method was used to determine fibrinogen activity. In addition, one of the two groups of type 2 diabetic patients receiving ordinary treatment was additionally treated with Lys for 3 months. Fibrinogen activity and some other parameters were evaluated in their plasma. RESULTS: The results indicated increases in the activity of glycated fibrinogen in both of the in vivo and in vitro experiments. Advanced glycation end products were increased by time, as shown using fluorometry in both the plasma of the diabetic patients and the incubation medium of protein with glucose. The circular dichroism spectra showed some changes in the fibrinogen secondary and tertiary structures after glycation. The electrophoretic mobility of the glycated fibrinogen changed and the cross-link formation between the fibrinogen subunits due to glycation was observed. Lys inhibited all of the mentioned fibrinogen changes both in the in vitro experiments and after its administration to the diabetic patients. CONCLUSION: Lys, as an inhibitor of protein glycation, improved fibrinogen's structure and function, both in vitro and in vivo.
RCT Entities:
INTRODUCTION:Fibrinogen is a plasma glycoprotein that participates in the hemostasis system. Its malfunction has been reported as a consequence of diabetic complications. In this study, the inhibitory effect of L-Lysine (Lys) on the nonenzymatic glycation of fibrinogen was investigated in both in vitro and in vivo conditions. MATERIALS AND METHODS:Fibrinogen was incubated with glucose in the presence or absence of Lys. Then, its structure was studied by fluorescence spectroscopy, circular dichroism, and electrophoresis. The Clauss method was used to determine fibrinogen activity. In addition, one of the two groups of type 2 diabeticpatients receiving ordinary treatment was additionally treated with Lys for 3 months. Fibrinogen activity and some other parameters were evaluated in their plasma. RESULTS: The results indicated increases in the activity of glycated fibrinogen in both of the in vivo and in vitro experiments. Advanced glycation end products were increased by time, as shown using fluorometry in both the plasma of the diabeticpatients and the incubation medium of protein with glucose. The circular dichroism spectra showed some changes in the fibrinogen secondary and tertiary structures after glycation. The electrophoretic mobility of the glycated fibrinogen changed and the cross-link formation between the fibrinogen subunits due to glycation was observed. Lys inhibited all of the mentioned fibrinogen changes both in the in vitro experiments and after its administration to the diabeticpatients. CONCLUSION:Lys, as an inhibitor of protein glycation, improved fibrinogen's structure and function, both in vitro and in vivo.
Authors: Leen Oyoun Alsoud; Nelson C Soares; Hamza M Al-Hroub; Muath Mousa; Violet Kasabri; Nailya Bulatova; Maysa Suyagh; Karem H Alzoubi; Waseem El-Huneidi; Bashaer Abu-Irmaileh; Yasser Bustanji; Mohammad H Semreen Journal: Metabolites Date: 2022-06-01
Authors: S Mehdi Ebrahimi; S Zahra Bathaie; Nassim Faridi; Mohammad Taghikhani; Manouchehr Nakhjavani; Soghrat Faghihzadeh Journal: PLoS One Date: 2019-12-19 Impact factor: 3.240
Authors: Judith J de Vries; Charlotte J M Snoek; Dingeman C Rijken; Moniek P M de Maat Journal: Arterioscler Thromb Vasc Biol Date: 2020-01-09 Impact factor: 8.311